Home › Research › Treatments
Dementia drug consumption in the Basque Country between 2006 and 2011
G Villanueva, M López de Argumedo, I Elizondo. Neurologia (Barcelona, Spain), 2014-11-11
Topic: Health services, long-term care and technology
Plain-language summary
Consumption increased by 49.72% between 2006 and 2011. There were marked differences between drugs (13.02% donepezil; 93.18% rivastigmine; 37.79% galantamine; 70.40% memantine) and Basque provinces (16.34% in Áraba; 50.49% in Bizkaia; 57.37% in Gipuzkoa). Likewise, expenditure increased from €11.5 million in 2006 to € 18.1 million in 2011. This study shows increased consumption of these drugs, although there are also marked differences by province which may be due to differences in prescribing habits. Spending for these drugs rose parallel to this increase in consumption; drug prices remained stable throughout the study period.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Villanueva, G., de Argumedo, M. L., & Elizondo, I. (2016). Dementia drug consumption in the Basque Country between 2006 and 2011. Neurologia (Barcelona, Spain). https://doi.org/10.1016/j.nrl.2014.09.006
Vancouver
Villanueva G, de Argumedo ML, Elizondo I. Dementia drug consumption in the Basque Country between 2006 and 2011. Neurologia (Barcelona, Spain). 2016. doi:10.1016/j.nrl.2014.09.006. PMID: 25449962.
BibTeX
@article{villanueva2016-25449962,
author = {Villanueva, G and de Argumedo, M López and Elizondo, I},
title = {{Dementia drug consumption in the Basque Country between 2006 and 2011}},
journal = {Neurologia (Barcelona, Spain)},
year = {2016},
doi = {10.1016/j.nrl.2014.09.006},
pmid = {25449962},
url = {https://doi.org/10.1016/j.nrl.2014.09.006}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Consumption increased by 49.72% between 2006 and 2011.
- There were marked differences between drugs (13.02% donepezil; 93.18% rivastigmine; 37.79% galantamine; 70.40% memantine) and Basque provinces (16.34% in Áraba; 50.49% in Bizkaia; 57.37% in Gipuzkoa).
- Likewise, expenditure increased from €11.5 million in 2006 to € 18.1 million in 2011.
- This study shows increased consumption of these drugs, although there are also marked differences by province which may be due to differences in prescribing habits.
- Spending for these drugs rose parallel to this increase in consumption; drug prices remained stable throughout the study period.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Effect sizeincreased by 49.72%; 13.02%; 93.18%
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 23 of the 56 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurologia (Barcelona, Spain)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25449962) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 23 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 23 of the 56 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “cholinesterase”
271 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 271 tagged studies.